@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech
@JohnCFierce: Love this stuff--Sanofi, Regeneron seize a regulatory shortcut in blockbuster PCSK9 race with Amgen. Story | Follow @JohnCFierce
@DamianFierce: Just wait until $GALT finds out what people on Friendster are saying. Story via Yahoo! Finance | Follow @DamianFierce
@EmilyMFierce: Merck aims to boost HPV vaccination rates amid lagging numbers. Story | Follow @EmilyMFierce
> FDA advisers are meeting today to review Baxter's HyQvia, an experimental therapy for primary immunodeficiency diseases. Approved in Europe, the treatment was earlier rejected by the FDA. Story
> Facing a variety of requests related to its European filing for the weight drug NB32, Orexigen ($OREX) says it will delay its response to the Day 180 List of Outstanding Issues by a month, filing them in Septermber. Release
Medical Device News
@FierceMedDev: Editor's Corner from @HollmerMark: In Q2, diagnostics venture investment showed some signs of life. Article | Follow @FierceMedDev
@StacyALawrence: Edwards stock surges on strong sales, profits due to legal settlement. Article | Follow @StacyALawrence
@VarunSaxena2: Johnson & Johnson to call for voluntary return of morcellators. WSJ story | Follow @VarunSaxena2
@MichaelGFierce: Scientists test a nanoparticle "alarm clock" to awaken immune systems put to sleep by cancer. Release | Follow @MichaelGFierce
@EmilyWFierce: Boston Scientific wins first vaginal mesh case to go to trial. Article | Follow @EmilyWFierce
> FDA advisory panel to consider PMA of TissuGlu surgical adhesive. Article
> Ablatherm ultrasound prostate cancer treatment rebuffed by FDA panel. More
> Fat freezer Zeltiq turns a surprise profit and climbs almost 30%. Story
Pharma News
@FiercePharma: ICYMI: Novartis reports high Bexsero uptake as it pushes ahead in open market. FierceVaccines story | Follow @FiercePharma
@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. Release | Follow @TracyStaton
@EricPFierce: Run-ins with the FDA continue to chew up the earnings at India's Ranbaxy. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI: This week's full issue of FiercePharmaMarketing. Report | Follow @CarlyHFierce
> Eyeing consumer health, Meda nabs Italy's Rottapharm in long-sought $3B deal. Article
> Novartis apologizes for lax business practices in Japan as side-effects scandal widens. More
Vaccines News
> Kenya study reveals new malaria vaccine targets. More
> Flu season should return Sanofi to double-digit vaccines growth, CEO says. Item
> Novartis reports high Bexsero uptake as it pushes ahead in open market. Story
> Merck aims to boost HPV vaccination rates amid lagging numbers. Article
> Pfizer finally lands vaccines bulk-up with $635M Baxter buy. News
Pharma Manufacturing News
> Pfizer buys a portion of a vaccine plant from Baxter, J&J sells a vax facility to PaxVax. Item
> Hospira's Rocky Mount plant meets FDA goals, but one in India does not. Article
> Ranbaxy rings up another loss as regulatory problems chew away profits. Story
> Spectacular warehouse burglary left extensive collateral damage for Eli Lilly. Article
> Manufacturing takes it on the chin in Amgen cuts. More